Journal of Oncology / 2016 / Article / Tab 1

Clinical Study

Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?

Table 1

Baseline characteristics of patients with hepatocellular carcinoma treated with transarterial chemoembolization.

mRECIST categories value
Complete
()
Partial
()
Stable
()
Progressive
()

Age (mean ± SD)61.5 ± 8.761.5 ± 10.163.1 ± 9.561.9 ± 8.30.697

Gender
 Female73 (71.6%)110 (79.7%)40 (71.4%)10 (63.5%)0.102
 Male29 (28.4%)28 (20.3%)23 (28.6%)4 (36.5%)

Race
 White78 (76.5%)105 (76.1%)43 (68.3%)7 (50.0%)0.064
 Black18 (17.7%)30 (21.7%)13 (20.6%)6 (42.9%)
 Other6 (5.8%)3 (2.2%)7 (11.1%)1 (7.1%)

Etiology
 Alcohol29 (28.4%)35 (25.4%)13 (21.0%)2 (14.3%)0.563
 HBV7 (6.9%)6 (4.4%)5 (7.9%)2 (14.3%)0.434
 HCV57 (55.9%)73 (52.9%)21 (33.9%)5 (35.7%)0.024
 NASH22 (21.6%)28 (20.3%)10 (15.9%)1 (7.1%)0.402

Child-Pugh class0.525
 A35 (34.3%)53 (38.4%)28 (44.4%)7 (50.0%)
 B54 (52.9%)74 (53.6%)28 (44.4%)7 (50.0%)
 C13 (12.8%)11 (8.0%)7 (11.2%)0 (0.0%)

AFP12.3 ± 100.822.0 ± 158.927.0 ± 132.6132.0 ± 3601.00.179

Diameter of largest tumor3.6 ± 1.84.6 ± 2.55.6 ± 4.46.1 ± 3.7<0.0001

Number of tumors1.6 ± 0.81.5 ± 1.02.1 ± 1.41.9 ± 1.60.003

Medians and interquartile range reported.
Kruskal-Wallis procedure used.
TACE: transarterial chemoembolization; mRECIST: modified Response Evaluation Criteria In Solid Tumors, value: probability, SD: standard deviation, HBV: hepatitis B virus, HCV: hepatitis C virus, NASH: nonalcoholic steatohepatitis, and AFP: alpha fetoprotein.